A weekly round-up of the
latest coverage in psychedelics.
Receive the free weekly digest straight to your inbox every week
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
March 30 – April 5, 2026
A Note From the Editor
Earlier this week, we learned that the state of Texas intends to move ahead with its ibogaine research program without the involvement of a single drug development company. Readers will recall that $50 million was carved out from the state’s budget last year to match private investment in ibogaine trials. However, no such company has been able to satisfy SB2308’s requirements, the state’s Health and Human Services Commission says, such as sharing royalties with Texas and having a corporate presence in the state.
As such, leaders in the Lone Star State say that they will go it alone, with some advocates saying that the state has committed to the full $100 million. We will be following this story closely.
Elsewhere this week, we published our first Quarterly Briefing video for Pα+ subscribers, which provides a 40-minute overview of developments across the psychedelic drug development, regulatory and policy, and research realms in the last three months, as well as a look ahead to Q2.
Lastly, to those of you who were hoping to pick up sporting goods featuring our Psychedelic Pipeline Bullseye, such as a dartboard or yoga mat, I am sorry to confirm that it was, indeed, an April Fool’s joke. If you insist, you can scratch that itch by printing out a copy of the PDF and getting crafty. Do send us photos!
Below, you will find your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelic business, policy, research and beyond.
Josh Hardman
Founder & Editor
Pα+
An insider’s guide to the business,
policy and science of psychedelics.
Basic
Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||